Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide Tablet, Film Coated
FDA Label NDC 0093-5002

38 label sections · Submitted to the FDA by Teva Pharmaceuticals Usa, Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Teva Pharmaceuticals Usa, Inc. for the product Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide (NDC 0093-5002). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding warning: fetal toxicity, 1 indications and usage, 2 dosage and administration, 3 dosage forms and strengths, 4 contraindications, 5.1 fetal toxicity, 5.2 hypotension in volume- or salt-depleted patients, 5.3 increased angina and/or myocardial infarction, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

* Please review the disclaimer below.